Matches in SemOpenAlex for { <https://semopenalex.org/work/W2899885364> ?p ?o ?g. }
- W2899885364 endingPage "762" @default.
- W2899885364 startingPage "752" @default.
- W2899885364 abstract "Inflammation is causally related to atherothrombosis. Treatment with canakinumab, a monoclonal antibody that inhibits inflammation by neutralizing interleukin-1β, resulted in a lower rate of cardiovascular events than placebo in a previous randomized trial. We sought to determine whether an alternative approach to inflammation inhibition with low-dose methotrexate might provide similar benefit.We conducted a randomized, double-blind trial of low-dose methotrexate (at a target dose of 15 to 20 mg weekly) or matching placebo in 4786 patients with previous myocardial infarction or multivessel coronary disease who additionally had either type 2 diabetes or the metabolic syndrome. All participants received 1 mg of folate daily. The primary end point at the onset of the trial was a composite of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. Near the conclusion of the trial, but before unblinding, hospitalization for unstable angina that led to urgent revascularization was added to the primary end point.The trial was stopped after a median follow-up of 2.3 years. Methotrexate did not result in lower interleukin-1β, interleukin-6, or C-reactive protein levels than placebo. The final primary end point occurred in 201 patients in the methotrexate group and in 207 in the placebo group (incidence rate, 4.13 vs. 4.31 per 100 person-years; hazard ratio, 0.96; 95% confidence interval [CI], 0.79 to 1.16). The original primary end point occurred in 170 patients in the methotrexate group and in 167 in the placebo group (incidence rate, 3.46 vs. 3.43 per 100 person-years; hazard ratio, 1.01; 95% CI, 0.82 to 1.25). Methotrexate was associated with elevations in liver-enzyme levels, reductions in leukocyte counts and hematocrit levels, and a higher incidence of non-basal-cell skin cancers than placebo.Among patients with stable atherosclerosis, low-dose methotrexate did not reduce levels of interleukin-1β, interleukin-6, or C-reactive protein and did not result in fewer cardiovascular events than placebo. (Funded by the National Heart, Lung, and Blood Institute; CIRT ClinicalTrials.gov number, NCT01594333.)." @default.
- W2899885364 created "2018-11-16" @default.
- W2899885364 creator A5003186890 @default.
- W2899885364 creator A5008947092 @default.
- W2899885364 creator A5009413704 @default.
- W2899885364 creator A5015428271 @default.
- W2899885364 creator A5018121224 @default.
- W2899885364 creator A5019471027 @default.
- W2899885364 creator A5021368492 @default.
- W2899885364 creator A5023039635 @default.
- W2899885364 creator A5023942807 @default.
- W2899885364 creator A5024863757 @default.
- W2899885364 creator A5025632184 @default.
- W2899885364 creator A5031554912 @default.
- W2899885364 creator A5036001636 @default.
- W2899885364 creator A5037322697 @default.
- W2899885364 creator A5039937213 @default.
- W2899885364 creator A5041415060 @default.
- W2899885364 creator A5043201732 @default.
- W2899885364 creator A5045857025 @default.
- W2899885364 creator A5050398307 @default.
- W2899885364 creator A5055685968 @default.
- W2899885364 creator A5063514037 @default.
- W2899885364 creator A5063978497 @default.
- W2899885364 creator A5069713967 @default.
- W2899885364 creator A5071021570 @default.
- W2899885364 creator A5072898800 @default.
- W2899885364 creator A5080334509 @default.
- W2899885364 creator A5091595592 @default.
- W2899885364 date "2019-02-21" @default.
- W2899885364 modified "2023-10-18" @default.
- W2899885364 title "Low-Dose Methotrexate for the Prevention of Atherosclerotic Events" @default.
- W2899885364 cites W1485133278 @default.
- W2899885364 cites W1552829599 @default.
- W2899885364 cites W2023380965 @default.
- W2899885364 cites W2094941678 @default.
- W2899885364 cites W2100260684 @default.
- W2899885364 cites W2111624359 @default.
- W2899885364 cites W2113187337 @default.
- W2899885364 cites W2115004354 @default.
- W2899885364 cites W2126384096 @default.
- W2899885364 cites W2155123856 @default.
- W2899885364 cites W2157940881 @default.
- W2899885364 cites W2166204514 @default.
- W2899885364 cites W2166732840 @default.
- W2899885364 cites W2222665820 @default.
- W2899885364 cites W2285780972 @default.
- W2899885364 cites W2331320446 @default.
- W2899885364 cites W2337488815 @default.
- W2899885364 cites W2342174771 @default.
- W2899885364 cites W2357015347 @default.
- W2899885364 cites W2748400555 @default.
- W2899885364 cites W2756894029 @default.
- W2899885364 cites W2767179147 @default.
- W2899885364 cites W2768492618 @default.
- W2899885364 cites W2769000982 @default.
- W2899885364 cites W2771544422 @default.
- W2899885364 cites W2888384778 @default.
- W2899885364 doi "https://doi.org/10.1056/nejmoa1809798" @default.
- W2899885364 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6587584" @default.
- W2899885364 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30415610" @default.
- W2899885364 hasPublicationYear "2019" @default.
- W2899885364 type Work @default.
- W2899885364 sameAs 2899885364 @default.
- W2899885364 citedByCount "807" @default.
- W2899885364 countsByYear W28998853642018 @default.
- W2899885364 countsByYear W28998853642019 @default.
- W2899885364 countsByYear W28998853642020 @default.
- W2899885364 countsByYear W28998853642021 @default.
- W2899885364 countsByYear W28998853642022 @default.
- W2899885364 countsByYear W28998853642023 @default.
- W2899885364 crossrefType "journal-article" @default.
- W2899885364 hasAuthorship W2899885364A5003186890 @default.
- W2899885364 hasAuthorship W2899885364A5008947092 @default.
- W2899885364 hasAuthorship W2899885364A5009413704 @default.
- W2899885364 hasAuthorship W2899885364A5015428271 @default.
- W2899885364 hasAuthorship W2899885364A5018121224 @default.
- W2899885364 hasAuthorship W2899885364A5019471027 @default.
- W2899885364 hasAuthorship W2899885364A5021368492 @default.
- W2899885364 hasAuthorship W2899885364A5023039635 @default.
- W2899885364 hasAuthorship W2899885364A5023942807 @default.
- W2899885364 hasAuthorship W2899885364A5024863757 @default.
- W2899885364 hasAuthorship W2899885364A5025632184 @default.
- W2899885364 hasAuthorship W2899885364A5031554912 @default.
- W2899885364 hasAuthorship W2899885364A5036001636 @default.
- W2899885364 hasAuthorship W2899885364A5037322697 @default.
- W2899885364 hasAuthorship W2899885364A5039937213 @default.
- W2899885364 hasAuthorship W2899885364A5041415060 @default.
- W2899885364 hasAuthorship W2899885364A5043201732 @default.
- W2899885364 hasAuthorship W2899885364A5045857025 @default.
- W2899885364 hasAuthorship W2899885364A5050398307 @default.
- W2899885364 hasAuthorship W2899885364A5055685968 @default.
- W2899885364 hasAuthorship W2899885364A5063514037 @default.
- W2899885364 hasAuthorship W2899885364A5063978497 @default.
- W2899885364 hasAuthorship W2899885364A5069713967 @default.
- W2899885364 hasAuthorship W2899885364A5071021570 @default.
- W2899885364 hasAuthorship W2899885364A5072898800 @default.
- W2899885364 hasAuthorship W2899885364A5080334509 @default.